Inventor · disambiguated record
Jacob Ravn
Also filed as: RAVN JACOB
17 granted patents·11 pending applications·42 citations·filing 2007–2025
91Inventor score
Top patents by PatentIndex Score
28 records- 0192US9879265B2Oligonucleotide conjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2014·Granted Jan 30, 2018·17 cites·34 claims
- 0289US11505569B2GalNAc phosphoramidites, nucleic acid conjugates thereof and their useHOFFMANN LA ROCHE·Filed 2020·Granted Nov 22, 2022·2 cites·2 claims
- 0387US12421516B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2023·Granted Sep 23, 2025·0 cites·26 claims
- 0487US10077443B2Oligonucleotide conjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2013·Granted Sep 18, 2018·10 cites·22 claims
- 0585US10358643B2Poly oligomer compound with biocleavable conjugatesHOFFMANN LA ROCHE·Filed 2015·Granted Jul 23, 2019·7 cites·18 claims
- 0681US11267843B2Stereodefining L-monomersROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Mar 8, 2022·2 cites·4 claims
- 0778US11739332B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Granted Aug 29, 2023·0 cites·21 claims
- 0878US10443058B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Oct 15, 2019·1 cites·10 claims
- 0978US10385342B2Methods of treatment using antisense oligomers and conjugates targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Granted Aug 20, 2019·1 cites·63 claims
- 1078US10370668B2Manufacture of antisense oligomers and conjugates targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Granted Aug 6, 2019·1 cites·45 claims
- 1175US11091764B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Granted Aug 17, 2021·0 cites·50 claims
- 1272US11261209B2Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotideROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Mar 1, 2022·1 cites·12 claims
- 1370US2025346894A2Antisense Oligonucleotide for Targeting ProgranulinHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1468US2021238601A1Oligonucleotide ConjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Application pending·0 cites
- 1566US11155816B2Oligonucleotide conjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Granted Oct 26, 2021·0 cites·24 claims
- 1665US12104153B2Antisense oligonucleotide for targeting progranulinHOFFMANN LA ROCHE·Filed 2021·Granted Oct 1, 2024·0 cites·10 claims
- 1763US11591594B2LNA-G processROCHE INNOVATION CT COPENHAGEN AS·Filed 2020·Granted Feb 28, 2023·0 cites·21 claims
- 1854US2023212572A1Guanosine Analogues for Use in Therapeutics PolynucleotidesROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Application pending·0 cites
- 1949US2018016575A1LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate LinkagesROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 2049US2022031730A1Enhanced oligonucleotides for modulating fubp1 expressionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2149US2018112217A1Stereospecific Phosphorothioate LNAROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 2242US2015368642A1Lna oligonucleotide carbohydrate conjugatesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 2342US2017327524A1Galnac phosphoramidites, nucleic acid conjugates thereof and their useHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 2442US2010062994A1Adenosine Receptor AntagonistsSANTARIS PHARMA AS·Filed 2007·Application pending·0 cites
- 2541US10815481B2Chiral library screenROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Granted Oct 27, 2020·0 cites·14 claims
- 2641US2019055550A1LNA-G ProcessROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Application pending·0 cites
- 2740US11248019B2Trityl-mono-GalNAc compounds and their useHOFFMANN LA ROCHE·Filed 2017·Granted Feb 15, 2022·0 cites·11 claims
- 2840US2025262317A1Linkers for site-specific antibody conjugationHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jacob Ravn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →